Article Per Year (5 Year)
p-Index From 2020 - 2025
0.444
P-Index
This Author published in this journals
All Journal Folia Medica Indonesiana CURRENT INTERNAL MEDICINE RESEARCH AND PRACTICE SURABAYA JOURNAL
Susanti, Luthfiana Rofhani
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health Other

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Efficacy and Safety of Ozoralizumab vs. Moxibustion for Rheumatoid Arthritis Susanti, Luthfiana Rofhani; Mustika, Arifa; Rahmawati, Lita Diah; Wungu, Citrawati Dyah Kencono
Folia Medica Indonesiana Vol. 60 No. 4 (2024): December
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/fmi.v60i4.64949

Abstract

Rheumatoid arthritis is a chronic inflammatory disease that symmetrically damages the synovial membrane, affecting approximately 13% of the global population. Systemic complications and substantial declines in quality of life may result from untreated rheumatoid arthritis. This study investigated the safety and efficacy of moxibustion and ozoralizumab in reducing disease activity scores in rheumatoid arthritis patients. Between July 2023 and February 2025, we conducted a thorough search on four online databases (PubMed, Cochrane, Scopus, and ProQuest) using keywords, reference searches, and other methods following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The obtained randomized controlled trials (RCTs) were assessed using the Cochrane Risk of Bias 2 (ROB2) tool. MetaInsight version 5.2.1 was utilized to perform the indirect network meta-analysis, using mean difference (MD) as the summary statistics. The measurement of the Disease Activity Score 28 (DAS28) indicated that ozoralizumab had a more significant effect on rheumatoid arthritis compared to placebo (MD=-1.88, 95% CI=-2.24-(-1.52)) and moxibustion (MD=-0.69, 95% CI=-1.07-0.31). Ozoralizumab demonstrated mild, moderate, and severe side effects, whereas moxibustion displayed modest side effects in comparison to placebo. In summary, both ozoralizumab and moxibustion reduced DAS28 in patients with rheumatoid arthritis, with ozoralizumab proving to be the more effective treatment. However, the adverse effects of ozoralizumab were more varied than those of moxibustion.
Efficacy of Ozoralizumab vs. Golimumab for Rheumatoid Arthritis: A Systematic Review Fithriyah, Nathania Elma; Rahmadhani, Khafiyah Hikmah; Susanti, Luthfiana Rofhani; Mustika, Arifa; Lita Diah Rahmawati; Wungu, Citrawati Dyah Kencono
Current Internal Medicine Research and Practice Surabaya Journal Vol. 6 No. 2 (2025): CURRENT INTERNAL MEDICINE RESEARCH AND PRACTICE SURABAYA JOURNAL
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/cimrj.v6i2.66406

Abstract

Introduction: Rheumatoid arthritis, a systemic autoimmune disease, affects 13% of the world population. As a well-established therapy, golimumab provides a key benchmark for assessing novel biological treatments. In contrast, ozoralizumab represents an innovative therapeutic approach. This study aimed to comprehensively elucidate the efficacy of golimumab and ozoralizumab in reducing rheumatoid arthritis disease activity. Methods: Literature searches were conducted throughout PubMed, Cochrane, and Web of Science using Boolean operators, covering available records from database inception until October 2024. The literature search was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The included studies were randomized controlled trials (RCT) evaluating the efficacy of ozoralizumab or golimumab for rheumatoid arthritis. Five studies from 2015 to 2022 were obtained and assessed using the Cochrane Risk of Bias 2 (ROB2) tool. Results: The five studies consisted of two ozoralizumab trials and three golimumab trials conducted in Japan and the United States, involving 2,305 participants. All included studies exhibited a low risk of bias based on assessments undertaken using the ROB2 tool. The differences in Disease Activity Score-28 (DAS28) remission rates between ozoralizumab and placebo were 42.6% in one study and 6.3% in the other, whereas golimumab mainly showed smaller differences versus placebo across three studies (4.6%, 5.9%, and 10.4%). Conclusion: This study demonstrates DAS28 remission in rheumatoid arthritis patients receiving either ozoralizumab or golimumab therapy. Nonetheless, further direct statistical studies are essential to determine which therapy is superior and under what circumstances it should be administered.   Highlights: 1. This study provides robust evidence that establishes ozoralizumab as a novel tumor necrosis factor-alpha (TNF-α) inhibitor for rheumatoid arthritis. 2. According to the findings, ozoralizumab may be a clinician's choice due to its comparable efficacy and potential advantages over golimumab.
Co-Authors Arifa Mustika Fithriyah, Nathania Elma Rahmadhani, Khafiyah Hikmah Rahmawati, Lita Diah Wungu, Citrawati Dyah Kencono Wungu, Citrawati Dyah Kencono